Last Updated : April 11, 2025
Details
Generic Name:
bulevirtide
Project Status:
Received
Therapeutic Area:
chronic hepatitis delta virus (HDV) infection
Manufacturer:
Gilead Sciences Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Hepcludex
Project Line:
Reimbursement Review
Project Number:
SR0881-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Bulevirtide is anticipated to be indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Bulevirtide is anticipated to be indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 22-Jan-25 |
|---|---|
| Call for patient/clinician input closed | 18-Mar-25 |
| Submission received | 09-Apr-25 |
| Submission accepted | - |
Last Updated : April 11, 2025